Cognizant Worldwide
Cognizant Worldwide is recorded as a service provider in 19 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 19 of 19 trials · Latest update first
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema [Donidalorsen Treatment in Children with Hereditary Angioedema]
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE).
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid
Sponsor Ipsen Pharma
- Start (EU)
- Latest update
- Estimated end
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participants.
Sponsor Clementia Pharmaceuticals Inc. An Ipsen Company
- Start (EU)
- Latest update
- Estimated end
An Integrated Phase I/II, Multicentre, Double-Blind, Randomised, Dysport and Placebo Controlled, Dose-Escalation and Dose-Finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity Followed by an Open-label Extension Period
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
- Not reported
C5751003 - AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
IL Believe: A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Sponsor Ascendis Pharma Oncology Division A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Open‑label Trial to Evaluate the Long‑term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy.
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
Sponsor Otsuka Pharmaceutical Development And Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
ION363-CS1: A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients with Fused in Sarcoma Mutations (FUS-ALS)
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
BelieveIT-201: A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Sponsor Ascendis Pharma Oncology Division A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.
Sponsor Otsuka Pharmaceutical Development And Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Sponsor Ascendis Pharma Oncology Division A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Cognizant Worldwide?
The 2026-10-09 snapshot links Cognizant Worldwide to 19 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Pharmacovigilence, Investigator Portal, PV case processing, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Cognizant Worldwide?
The most frequently recorded therapeutic areas are Immunology, Genetic and Congenital Disorders, Allergy, Blood Disorders. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Cognizant Worldwide conducted?
The linked trials record locations in 21 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where Cognizant Worldwide delivered services.
What can this page tell me about Cognizant Worldwide's trial experience?
Browse 19 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Cognizant Worldwide. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Cognizant Worldwide Limited